JohnCarlHornbergerMDMS

PubMed

• 4 citations
  Opioid Misuse: A Global Crisis.
  John Hornberger, Jagpreet Chhatwal> ;Value in Health. 2021 Jan 13
• Letter in reply.
  Lou Hochheiser, John Hornberger, Michelle Turner, Gary H. Lyman> ;Journal of Comparative Effectiveness Research. 2019 Nov 1
• 8 citations
  ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
  Tyler J. O’Neill, Rebecca A. Miksad, Danelle Miller, Lesley Maloney, Ani John, Carolyn Hiller, John Hornberger> ;Value in Health. 2019 Jul 1
• 4 citations
  A Promising New Strategy to Improve Treatment Outcomes for Patients with Depression.
  George Carpenter, Henry T. Harbin, Robin L. Smith, John Hornberger, David B. Nash> ;Population Health Management. 2019 May 30
• 3 citations
  Further Consideration of the Pigmented Lesion Assay-Reply.
  Daniel M. Siegel, John Hornberger> ;JAMA Dermatology. 2019 Mar 1
• 9 citations
  Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer.
  Lou Hochheiser, John Hornberger, Michelle Turner, Gary H. Lyman> ;Journal of Comparative Effectiveness Research. 2019 Jan 21
• 20 citations
  Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions.
  John Hornberger, Daniel M Siegel> ;JAMA Dermatology. 2018 Sep 1
• 13 citations
  Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast canc...
  Delphine Hequet, Céline Callens, David Gentien, Benoit Albaud, Marie-Ange Mouret-Reynier, Coraline Dubot, Paul Cottu, Cyrille Huchon, Sonia Zilberman, Helene Berseneff...> ;Plos One. 2017 Oct 18
• 3 citations
  Serious Adverse Events Associated with Readmission Through One Year After Vertebral Augmentation with Either a Polyetheretherketone Implant or Balloon Kyphoplasty.
  Douglas P. Beall, Jeffrey D Coe, Mark McIlduff, Daniel Bloch, John Hornberger, Christopher Warner, Sean Tutton> ;Pain Physician. 2017 Sep 1
• 26 citations
  Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis
  Jacob Sands, Qianyi Li, John Hornberger> ;Lung Cancer. 2017 Aug 1
• 25 citations
  Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.
  John Hornberger, Jay Bae, Ian A. Watson, Joseph A. Johnston, Michael Happich> ;Current Medical Research and Opinion. 2017 Jan 24
• 75 citations
  The burden of mental disorders in the eastern Mediterranean region, 1990–2013
  Raghid Charara, Mohammad H. Forouzanfar, Mohsen Naghavi, Maziar Moradi-Lakeh, Ashkan Afshin, Theo Vos, Farah Daoud, Haidong Wang, Charbel El Bcheraoui, Ibrahim A Khali...> ;Plos One. 2017 Jan 17
• 21 citations
  The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment ...
  Rachel Wuerstlein, Karl Sotlar, O Gluz, Burkhard Otremba, R von Schumann, I Witzel, Christian Schindlbeck, Wolfgang Janni, Christian Schem, Ingo Bauerfeind, S. Hasmuel...> ;Current Medical Research and Opinion. 2016 Mar 30
• 18 citations
  The VA Point-of-Care Precision Oncology Program: Balancing Access with Rapid Learning in Molecular Cancer Medicine
  Louis D. Fiore, Mary Brophy, Sara Turek, Valmeek Kudesia, Nithya Ramnath, Colleen Shannon, Ryan Ferguson, Saiju Pyarajan, Melissa Fiore, John Hornberger, Philip W. Lavori> ;Biomarkers in Cancer. 2016 Feb 29
• 7 citations
  Cost-effectiveness analysis of a multivariate index assay compared to modified American College of Obstetricians and Gynecologists criteria and CA-125 in the triage of...
  G.K. Forde, John Hornberger, S. Michalopoulos, Robert E. Bristow> ;Current Medical Research and Opinion. 2016 Feb 1
• 12 citations
  Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis
  Kaleb Michaud, Vibeke Strand, Nancy A. Shadick, Irina Degtiar, Kerri Ford, Steven N. Michalopoulos, John Hornberger> ;Rheumatology. 2015 Sep 1
• 6478 citations
  Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a sy...
  Theo Vos, Ryan M Barber, Brad Bell, Amelia Bertozzi-Villa, Stan Biryukov, Ian Bolliger, Fiona J Charlson, Adrian Davis, Louisa Degenhardt, Daniel Dicker, Leilei Duan, ...> ;Lancet. 2015 Aug 22
• 29 citations
  Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients.
  John Hornberger, Qianyi Li, Bruce Quinn> ;The American Journal of Managed Care. 2015 Jun 1
• 14 citations
  Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
  John Hornberger, Steven N. Michalopoulos, Minghan Dai, Paula Andrade, Tatiana Dilla, Michael Happich> ;The Journal of Mental Health Policy and Economics. 2015 Jun 1
• 31 citations
  An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population
  Peter Benn, Kirsten J. Curnow, Steven Chapman, Steven N. Michalopoulos, John Hornberger, Matthew Rabinowitz> ;Plos One. 2015 Jul 9
• 15 citations
  Impact of a Genomic Classifier of Metastatic Risk on Postprostatectomy Treatment Recommendations by Radiation Oncologists and Urologists.
  Paul L Nguyen, Heesun Shin, Kasra Yousefi, Darby J Thompson, John Hornberger, Andrew S Hyatt, Ketan K Badani, Todd M Morgan, Felix Y Feng> ;Urology. 2015 Jul 1
• 22 citations
  Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial
  John Hornberger, Fred R. Hirsch, Qianyi Li, Ray D. Page> ;Lung Cancer. 2015 May 1
• 15 citations
  Economic Analysis of Kiva VCF Treatment System Compared to Balloon Kyphoplasty Using Randomized Kiva Safety and Effectiveness Trial (KAST) Data
  Douglas P. Beall, Wayne J. Olan, Priyanka Kakad, Qianyi Li, John Hornberger> ;Pain Physician. 2015 May 1
• 28 citations
  Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal grow...
  Miguel Martín, Milagros González-Rivera, Serafin Morales, Juan de la Haba-Rodriguez, Lucía González-Cortijo, Luis Manso, Joan Albanell, Antonio González-Martín, Sonia ...> ;Current Medical Research and Opinion. 2015 Apr 8
• 9 citations
  The Clinical and Economic Implications of Specimen Provenance Complications in Diagnostic Prostate Biopsies
  Kirk J. Wojno, John Hornberger, Paul F. Schellhammer, Minghan Dai, Travis Morgan> ;The Journal of Urology. 2015 Apr 1
• Join now to see all

Journal Articles

• Economic Analysis of a Noninvasive Molecular Pathologic Assay for Pigmented Skin Lesions  
  John Hornberger, MD, JAMA
• Assigning value to medical algorithms - implications for personalized medicine  
  Hornberger J, Personalized Medicine, 1/1/2013
• Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group  
  Badani K, Thompson DJS, Buerki C, Davicioni E, Garrison J, Ghadessi M, Mitra MP, Wood PJ, Hornberger J, Oncotarget, 1/1/2013
• Editorial to Computer modeling of diabetes and its complications: A report on the Fifth Mount Hood Challenge Meeting  
  Hornberger J, Value Health, 1/1/2013
• Serum-based proteomic mass spectrometry test impacts clinical treatment decisions for patients with advanced non-small cell lung cancer  
  Ackerly WL, Nelson RE, Cowie RH, Spinella DG, Hornberger J, Curr Med Research Opinion, 1/1/2013
• Is personalized medicine cost-effective?  
  Hornberger J, Amer Health Drug Benefits, 1/1/2013
• Comparative effectiveness in personalized medicine - clearly defining the intended use population  
  Hornberger J, Value Health, 1/1/2013
• Cost-benefit of 21-gene Breast Cancer Recurrence Score for Patients in Singapore  
  de Lima Lopes G, Chien R, Hornberger J, Breast J, 1/1/2013
• Response to Lamy et al Role of serine protease urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor (PAI) type-1 as biomarkers in early stage...  
  Hornberger J, Gradishar WJ, Alvarado M, Chien R, Yu T, Gutierrez H, J Natl Cancer Inst, 1/1/2012
• A multi-gene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs  
  Hornberger J, Lyman G, Chien R, Meropol N, Value Health, 1/1/2012
• Challenges in the development and reimbursement of personalized medicine–payer and manufacturer perspectives and implications for health economics and outcomes researc...  
  Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf A, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J, Value Health, 1/1/2012
• Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis, treatment, and su...  
  Nystrom J, Hornberger J, Varadhachary G, Hornberger R, Gutierrez H, Henner W, Becker S, Amin M, Walker M, Oncotarget, 1/1/2012
• Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphocytic leukemia after responding to first-line rituximab plus chemo...  
  Hornberger J, Chien R, Friedmann M, Han L, Shewade A, Satram-Hoang S, Reyes C, Leuk Lymphoma, 1/1/2012
• Financial Implications of Choice of Dialysis Type of the Revised Medicare Payment System: An Economic Analysis  
  Hornberger J, Hirth R, Am J Kidney Diseases, 1/1/2012
• US Insurance Program’s Experience with a Multigene Assay for Early-Stage Breast Cancer  
  Hornberger J, Chien R, Krebs K, Hochheiser L, J Oncol Pract; Am J Manag Care, 1/1/2011
• Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy  
  Hornberger J, Simpson K, Shewade A, Dietz B, Baran R, Podsadecki T, Adv Ther, 1/1/2010
• Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli managed healthcare organization  
  Klang S, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J, Value Health, 1/1/2010
• Economic implications of 21-gene recurrence score assay: US multicenter experience  
  Hornberger J, Lyman GH, Chien R, J Clin Oncol, 1/1/2010
• Obstacles and proposed solutions to effective antiretroviral therapy in resource-limited settings  
  Bartlett J, Hornberger J, Shewade A, Bhor M, Rajagopalan R, JIAPAC, 1/1/2009
• Cost consequences of HIV-associated lipoatrophy  
  Hornberger J, Rajagopalan R, Shewade A, Loutfy MR, AIDS Care, 1/1/2009
• Review of “Electronic Health Records Guidelines for Clinicians and Administrators”  
  Hornberger J, JAMA, 1/1/2009
• Rechargeable Spinal Cord Stimulation System versus Nonrechargeable System for Patients with Failed Back Surgery Syndrome: A Cost-Consequences Analysis  
  Hornberger J, Hernandez J, Clark MA, et al, Clin J Pain, 1/1/2008
• Economic Evaluation of Rituximab plus cyclophosphamide, vincristine and prednisolone (CVP) for Advanced Follicular Lymphoma  
  Hornberger J, Reyes C, Valente N, et al, Leuk Lymph, 1/1/2008
• Relationship between antiretroviral prescribing patterns and treatment guidelines in treatment-Naïve, HIV-1 infected US veterans: 1992-2004  
  Holodniy M, Hornberger J, Rapoport D. et al, JAIDS, 1/1/2007
• Cost-effectiveness of a vaccine to prevent herpes zoster in older adults  
  Hornberger J, Robertus K, Ann Intern Med, 1/1/2006
• Join now to see all

Books/Book Chapters

• Klinische Nephrologie. 
  Chapter: Economic Considerations of the Hemodialysis Prescription. 
  Hornberger JEditors: HE Franz.Verlag, Landsberg1995
• Renal Physicians Association's Report 
  Chapter: Clinical Practice Guidelines on Adequacy of Hemodialysis 
  Hornberger J (Co-author)1993
• Japan's Health System. Efficiency and Effectiveness in Universal Care 
  Chapter: Chapter 14. Renal dialysis in Japan. 
  Hornberger J, Yoshikawa A, Holt MFaulkner & Gray, Washington,DC1993
• Proceedings of the Fifteenth Annual Symposium on Computer Applications in Medical Care 
  Chapter: Computer-assisted quality of life assessment for clinical trials. 
  Lenert LA, Hornberger JEditors: Kingsland LC.IEEE Computer Society, Washington, DC1991
• Join now to see all

Abstracts/Posters

• How are coverage decisions made in publicly-funded healthcare programs in low- and middle-income countries?
  Hornberger J, Shewade A, Gutierrez H, International Society for Pharmacoeconomic and Outcomes Research (ISPOR) 16th Annual International Meeting, Baltimore, MD, 1/1/2011
• Economic impact of rituximab as maintenance therapy in previously untreated follicular non-Hodgkin lymphoma.
  Hornberger J, Friedmann M, Han L, Chien R, Hornberger R, Satram-Hoang S, Reyes C, CAJ Clin Oncol, 1/1/2011
• Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Canada.
  Redding L, Hornberger J, Cowen JW, Chien R, Wang M, Annual Conference of Canadian Association of Population Therapeutics, Ottawa, Canada, 1/1/2011
• Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice.
  Hornberger J, Chien R, 12th St. Gallen International Breast Cancer Conference, St. Gallen, Switzerland, 1/1/2011
• Cost-effectiveness of Oncotype DX breast cancer assay in Singapore.
  De Lima Lopes G, Chien R, Hornberger J, 12th St. Gallen International Breast Cancer Conference, St. Gallen, Switzerland, 1/1/2011
• Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Canada.
  Redding L, Hornberger J, Cowen JW, Chien R, Wang M, CADTH Symposium, Vancouver, Canada, 1/1/2011
• Use of a multigene prognostic assay for selection of adjuvant chemotherapy in patients with stage II colon cancer: impact on quality-adjusted life expectancy and costs.
  Meropol N, Lyman G, Chien R, Hornberger J, Gastrointestinal Cancer Symposium, American Society of Clinical Oncology., San Francisco, CA, 1/1/2011
• LDT-SynFrame: An approach for assessing laboratory developed tests synthesized from prior appraisal frameworks, Genetic Testing and Molecular Biomarkers.
  Hornberger J, Chien R, Doberne J, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, Baltimore, MD, 1/1/2010
• Economics of a multigene assay to predict recurrence for early-stage breast cancer.
  Hornberger J, Chien R, Krebs K and Hochheiser, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, Baltimore, MD, 1/1/2010
• Meta-analysis of the decision impact of the 21-gene breast cancer Recurrence Score in clinical practice.
  Hornberger J , Chien R, 34th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, 1/1/2010
• Economic evaluation of Oncotype DX® to target chemotherapy use in lymph-node negative, oestrogen positive, early-stage breast cancer in Ireland.
  Lacey L and Hornberger J, 13th Annual European Congress, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Prague, Czech Republic, 1/1/2010
• Cost-benefit of Oncotype DX breast cancer assay in Singapore.
  De Lima Lopes G, Chien R, Hornberger J, 4th Annual Asian-Pacific Congress, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Phuket, Thailand, 1/1/2010
• An open-source, interactive model to assess the outcomes and economics of diabetes interventions.
  Hornberger J, Shewade A, Rickert J, Hammer M, Groleau D, Adams J, Annual Conference of the Canadian Association for Population Therapeutics (CAPT), Toronto, Canada, 1/1/2010
• An open-source, interactive model to assess the outcomes and economics of diabetes interventions in Canada.
  Hornberger J, Shewade A, Rickert J, Hammer M, Groleau D, Adams J, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th Annual International Meeting, Atlanta, GA, 1/1/2010
• Cost-effectiveness of rituximab, fludarabine, and cyclophosphamide (R-FC) in patients with previously untreated chronic lymphocytic leukemia (CLL).
  Hornberger J, Reyes C, Shewade A, Friedmann M, Chan L, Gutierrez H, Satram-Hoang S, Lerner S, Keating M, American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, 1/1/2010
• The cost-effectiveness of bortezomib for relapsed/refractory multiple myeloma – a Nordic comparison.
  Liwing J, GjonnesL, Sandberg I, Renlund M, Aschan J, Lothgren M, Rickert J, Hornberger J, Dhawan R, ISPOR 12th Annual European Congress, Paris, France, 1/1/2009
• A Systematic Literature Review of Utilities Associated With Visual Acuity in Retinal Diseases.
  Hornberger J, Shewade A, Doberne J, Kowalski J, Nguyen H, ARVO Annual Meeting, Ft. Lauderdale, FL, 1/1/2008
• Cost consequences of HIV-associated lipoatrophy.
  Hornberger J, Rajagoapalan R, Shewade A, Loutfy M, Ninth International Congress on Drug Therapy in HIV Infection, (HIV 9), Glasgow, U.K., 1/1/2008
• Cost-effectiveness of Rituximab plus CVP for first-line treatment of advanced indolent lymphoma.
  Hornberger J, Reyes C, Verhulst E, Lubeck D, Valente N, ASCO Annual Meeting, Chicago, IL, 1/1/2007
• Cost-Effectiveness of Rituximab Post CVP Induction for the Treatment of Low-Grade NHL.
  Hornberger J, Reyes C, Shewade A, Loecke D, Valente N, ASH Annual Meeting, Atlanta, GA, 1/1/2007
• 21-gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) breast cancer: An economic analysis including prognostic and predictive information.
  Cosler L, Kuderer N, Hornberger J, Lyman G, ASCO Annual Meeting, Atlanta, GA, 1/1/2006
• Review of economic appraisals of chemotherapy for metastatic colorectal cancer.
  Hornberger J, Robertus K, Bhattacharyya S, Deeter R, ISPOR Eleventh Annual International Meeting, Philadelphia, PA, 1/1/2006
• Cost-utility of stenting for symptomatic intracranial atherosclerotic disease.
  Hornberger J, Robertus K, Deuber N, Reyes C, Hernandez J, Bose A, ISPOR Tenth Annual International Meeting, Washington, DC, 1/1/2005
• Economic analysis of targeting chemotherapy (CT) using a 21 gene RT-PCR assay in lymph node negative (LN-), estrogen receptor positive (ER+) early-stage breast cancer ...
  Cosler L, Hornberger J, Lyman G, ASCO Annual Meeting, New Orleans, LA, 1/1/2004
• Cost-effectiveness of treating adults with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (PNALT) with peginterferon alfa-2A (40KD) (PEGASY...
  Hornberger J, Farci P, Prati D, Zuezem S, Patel K, Green J, ISPOR Ninth Annual International Meeting, Arlington, VA, 1/1/2004
• Join now to see all

Lectures

• Payment Reform in the United States – A Town-Hall Meeting of the American Society of Clinical Oncology 
  Chicago, IL - 5/31/2014
• The Biggest Threat to Personalized Medicine – Not Paying For Algorithms 
  Silicon Valley, Mountainview, CA - 1/28/2013
• Reimbursement – The Good, the Bad, and the Ugly 
  Boston, MA - 9/4/2012
• An open-source, interactive model to assess the outcomes and economics of diabetes interventions in Canada. 
  Malmo, Sweden - 9/18/2010
• Evaluate and Meet Standards for Generating Credible, Useful Evidence 
  San Diego, CA - 2/22/2010
• How Will Comparative Effectiveness Impact Medical Device Companies? (Panelist) 
  10/12/2009
• Reimbursement and Healthcare Reform 
  Santa Clara University, CA - 6/25/2009
• Pharmacoeconomics, Cost Effectiveness, and Outcome Analysis for Personalized Medicine 
  San Diego, CA - 6/21/2009
• Gaining Coverage and Reimbursement in the Age of Comparative Effectiveness 
  Palo Alto, CA - 6/1/2009
• A Roadmap for Knowing What Works in Health Care: Will a US National Clinical Effectiveness Center or the ARRA’s Comparative Effectiveness Research Program Show the Way... 
  Orlando, FL - 5/16/2009
• A Revised Framework for Appraising Novel Molecular Classifiers (Workshop Presenter) 
  Orlando, FL - 5/16/2009
• Economics of HIV Care (Invited Lecture) 
  Miami, FL - 1/1/2004
• Cost-effectiveness of Rituximab for treatment of patients with large B-cell lymphoma. (Invited Lecture) 
  Harvard University - 1/1/2001
• Pharmacogenomics and Ethical Implications of Drug Development 
  Chiron Park, Emeryville, CA - 1/1/2001
• Pharmacogenomics in Drug Development 
  Washington, DC - 1/1/2001
• Economic Challenges in Developing Pharmacogenomic Products 
  Tuscon, AZ - 1/1/2001
• Herceptin: Targeted Biologic Therapy for Patients with HER2 Protein Overexpressing Metastatic Breast Cancer 
  Tuscon, AZ - 1/1/2001
• Bayesian Analysis: An Introduction 
  Washington, DC - 1/1/1998
• Undertaking cost-beneficial trials in an era of managed care. 
  San Diego, CA - 1/1/1997
• Designing cost-effective clinical studies. 
  Indiana, IN - 1/1/1996
• Costs of interpreter services. 
  Washington, DC - 1/1/1995
• The economics of addressing patients' concerns. 
  Boston, MA - 1/1/1995
• Consistency of quality-of-life instruments 
  The University of North Carolina, Chapel Hill - 1/1/1995
• A novel method for providing interpreter services using remote-simultaneous interpretation. 
  Washington, DC - 1/1/1995
• Technical aspects of guideline development 
  La Jolla, CA - 1/1/1993
• Join now to see all

Other

• National forecasts of ADAP expenditures. 
  Hornberger J, Chun R, MaCurdy T
  1/1/2004
• Fiscal implications of Salt Lake County’s Health Access Project: A Hospital Perspective. 
  Hornberger J, Rapoport D, Marrufo G, HRSA
  10/1/2003
• Master's Thesis: “High-flux dialysis: A technology assessment” 
  Hornberger J, Stanford University
  1/1/1991